GlassScriptPhysician profile
John Steven Bruch
NPI 1447202023
$3,687.39
in general payments reported to CMS, 2019-2025
39 companies · $897 in 2025
The $897 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $107 · 2021: $38.67 · 2022: $474 · 2023: $666 · 2024: $880 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391 · Education: $52.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,391.36 |
| Education | $52.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $361.19 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $317.50 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Abbott Laboratories | $285.44 | 2019-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $282.51 | 2024 | Ilet Bionic Pancreas |
| Dexcom, INC. | $268.59 | 2022-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $209.33 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $205.22 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $140.09 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $137.23 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $129.92 | 2019-2024 | Korlym |
| Amgen INC. | $118.11 | 2019-2025 | Repatha, Tepezza |
| Medtronic Minimed, INC. | $108.47 | 2019 | |
| Abbvie INC. | $102.06 | 2019-2025 | Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.43 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Radius Health, INC. | $76.70 | 2019-2025 | Tymlos |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.56 | 2019-2025 | |
| Lifescan, INC. | $67.22 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $66.34 | 2023-2025 | |
| Madrigal Pharmaceuticals | $55.66 | 2025 | Rezdiffra |
| Cequr Corporation | $53.13 | 2022-2024 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $51.22 | 2019-2020 | |
| Antares Pharma, INC. | $49.49 | 2019-2025 | Xyosted |
| Chiesi USA, INC. | $49.01 | 2025 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $43.34 | 2025 | Strensiq |
| Sequel Med Tech, LLC | $41.94 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $38.29 | 2023-2024 | |
| Becton, Dickinson and Company | $34.62 | 2019 | |
| Mannkind Corporation | $33.99 | 2019-2023 | Afrezza |
| Zealand Pharma US, INC. | $26.04 | 2021 | |
| Ascendis Pharma Endocrinology INC | $25.61 | 2025 | Yorvipath |
| Intuity Medical INC | $23.92 | 2022 | |
| Embecta Corp. | $20.29 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Shire North American Group INC | $19.78 | 2019 | |
| Recordati_rare_diseases_inc. | $17.73 | 2024 | Signifor Lar, Isturisa |
| Medtronic, INC. | $17.18 | 2023 | Minimed 780g |
| Valeritas, INC. | $15.49 | 2019 | |
| Ibsa Pharma INC. | $14.69 | 2024 | Tirosint, Licart, Flector |
| Astrazeneca Pharmaceuticals LP | $12.06 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bruch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.